ClinicalTrials.Veeva

Menu

Efficacy Evaluation of Avance QQ Collagen for Skin Beautification

T

TCI

Status

Completed

Conditions

Skin Condition
Liposomal Encapsulation

Treatments

Dietary Supplement: Non-liposomal collagen drink
Dietary Supplement: Liposomal collagen drink
Dietary Supplement: Placebo drink

Study type

Interventional

Funder types

Industry

Identifiers

NCT06771388
24-088-B

Details and patient eligibility

About

To assess Avance QQ Collagen product on skin condition improvement

Enrollment

75 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Healthy male or female adults, age above 18 years old;
  • The grade of crow's feet above 2 (Han et al. Sci Rep 13, 18903 (2023));
  • Commitment not to use products having activity comparable with that of the product to be tested during the study period;
  • Free of any dermatological or systemic disorder that would interfere with results.

Exclusion criteria

  • Subject with obvious skin surface damage;
  • Subject who had oral or topical medication which may affect skin condition within 1 month;
  • Subject who is a vegetarian or likely to be acutely allergic to the listed ingredients in the product;
  • Female who is pregnant, nursing or planning to become pregnant during the course of the study;
  • Received facial laser therapy, chemical peeling in the past 2 months.

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

75 participants in 3 patient groups, including a placebo group

Placebo drink
Placebo Comparator group
Treatment:
Dietary Supplement: Placebo drink
Non-liposomal collagen drink
Active Comparator group
Treatment:
Dietary Supplement: Non-liposomal collagen drink
Liposomal collagen drink
Experimental group
Treatment:
Dietary Supplement: Liposomal collagen drink

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems